Page 10 - Initial Results News Today : Breaking News, Live Updates & Top Stories | Vimarsana

MEI Pharma and Kyowa Kirin Announce New Clinical Data on Zandelisib at American Society of Clinical Oncology Annual Meeting 2021 -Zandelisib, an investigational agent, +/- rituximab demonstrated 82% overall response rate in patients with relapsed or refractory (r/r) follicular lymphoma (FL) who had progression of disease within 24 months of first line chemoimmunotherapy (POD24); overall response rate of 93% in non-POD24- -An 8% discontinuation rate was observed in the combined study population- -Zandelisib and zanubrutinib combination therapy demonstrated 100% response rate in patients with r...

 E-Mail Targeted neuromodulation tailored to individual patients' distinctive symptoms is an increasingly common way of correcting misfiring brain circuits in people with epilepsy or Parkinson's disease. Now, scientists at UC San Francisco's Dolby Family Center for Mood Disorders have demonstrated a novel personalized neuromodulation approach that -- at least in one patient -- was able to provide relief from symptoms of severe treatment-resistant depression within minutes. The approach is being developed specifically as a potential treatment for the significant fraction of people with debili...

Tocvan Completes Phase One Drilling and Provides Update Calgary, Alberta – TheNewswire December 22, 2020. TOCVAN Ventures Corp. is pleased to announce the completion of its maiden drill program at the Pilar Gold-Silver Project in Sonora, Mexico. A total of 1,505 meters of reverse circulation drilling was completed in nine drill holes. All samples have been submitted to the lab in Hermosillo, results are expected in early 2021 and will be released in batches as they are … (TheNewswire) Calgary, Alberta – TheNewswire December 22, 2020. TOCVAN Ventures Corp. ( CSE:TOC) (CNSX:TOC.CN) (“...